Towards Universal Chemosensory Testing
CME Disclosure Information
Nov 5-7th, 2023

Sponsored by the The Ohio State University Wexner Medical Center and the Center for Continuing Medical Education in cooperation with the Department of Otolaryngology – Head and Neck Surgery.

Accreditation Statement
The Ohio State University Center for Continuing Medical Education (CCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Ohio State University Center for Continuing Medical Education designates this live activity and video recordings of the live activity (enduring material) for a maximum of 11 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning formats as described by AMA (include one in above AMA Credit Designation Statement)
- live activity
- enduring material
- journal-based CME activity
- test-item writing activity
- manuscript review activity
- PI CME activity
- internet point-of-care activity

CCME Disclosure Statement
As a provider of AMA PRA Category 1 Continuing Medical Education, it is the policy of CCME to adhere to the ACCME Standards for Commercial Support to avoid any conflict of interest and/or commercial bias and must ensure balance, independence, objectivity and scientific rigor in all its sponsored educational activities. All individuals who are in a position to control content of an educational activity, including presenters, panel members and moderators, must disclose any relevant financial relationships that create a conflict of interest.

Nothing in this program is intended to imply that any off-label or unapproved product use discussed is reimbursed by any government or private payer or that submission of a claim for such use is proper.

Planning Committee Disclosure Statements

Kai Zhao, Ph.D., discloses that he is a paid consultant to Diceros Therapeutics, Inc, a startup company developing topical nasal drug delivery devices, however, this financial relationship is not relevant to the proposed CME activity. His educational unit does not have a financial interest or affiliation with an organization that may receive direct benefit from the subject of the proposed CME activity and he will not be personally compensated for his role in the planning or execution of this proposed CME activity by an organization other than The Ohio State University.

Valentina Parma, Ph.D., discloses that she is a paid consultant and speaker to Sanofi, Inc, however, this financial relationship is not relevant to the proposed CME activity. Her educational
unit does not have a financial interest or affiliation with an organization that may receive direct benefit from the subject of the proposed CME activity and she will not be personally compensated for his role in the planning or execution of this proposed CME activity by an organization other than her home institute.

**Mark Albers, MD PhD** discloses that he is a co-founder and equity owner in Aromha, Inc, a startup company battling against Alzheimer’s Disease and other neurodegenerative diseases including Parkinson’s Disease using novel smell testing tools. His role as a planner committee member organizer, session chair, and discussion leader will not be influenced by commercial interests. His presentation will only contain his original work as well as sourced work from peer reviewed publications. He will not mention the commercial entity, except for the purpose of disclosure and all commercial logos will be removed. His educational unit (Massachusetts General Hospital and Harvard Medical School) does not have a financial interest or affiliation with Aromha, Inc., will not receive directly benefit from the subject of the proposed CME activity, including licensing fees or patent costs. He will not be personally compensated for his role in the planning or execution of this proposed CME activity by an organization other than his home institutions. He also discloses several other financial relationships that are not relevant to proposed CME activity. He will not mention these commercial entities at all.

**Steven D. Munger, PhD** discloses that he is a Co-owner and Chief Executive Officer of Redolynt, Inc., a startup company that has obtained an NIH STTR grant to assess The Adaptive Olfactory Measure of Threshold (ArOMa-T), a smell test technology co-invented by Dr. Munger and owned by University of Florida and other university partners. His role as a planner committee member organizer, session chair, and discussion leader will not be influenced by commercial interests. He will not mention the commercial entity, except for the purpose of disclosure, and no commercial logos will be used. He will not be personally compensated for his role in the planning or execution of this proposed CME activity by an organization other than his home institutions.

**Speaker Disclosure Statements**

The following *speakers* for this program have no relevant financial relationships with commercial interests to disclose, and their presentations will not include discussion of unapproved or “off-label” usage of commercial products and/or devices:

- **CHRISTOPHER SIMONS, PHD**
- **PAULE JOSEPH, PHD**
- **EDMUND PRIBITKIN, MD, MBA**
- **FRANK FRANKLIN, PHD, JD, MPH**
- **JENNIFER DOUGLAS, MD**
- **HOWARD HOFFMAN, MA**
- **SUSAN COLDWELL, PHD**
- **VALERIE DUFFY, PHD**
- **JULIE MENNELLA, PHD**
- **M. YANINA PEPINO, PHD**
- **PATRICE HUBERT, PHD**
- **MARIANNA OBRIST, PHD**

**Duncan Boak**, discloses that he is the Chief Executive of Fifth Sense, a patient advocate and charity group based in the UK that support people affected by smell and taste disorders across the world. He personally have no financial relationships with ineligible companies, however Fifth Sense has received funding from the following organizations within the last 24 months: Sanofi, GSK and Medtronic for Sponsorship of 2021 Fifth Sense Conference and 2022 volunteer forum. The relationship is ongoing but no further funding has been provided. He will not mention anything related to the sponsorship in any of his talks, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.
Katie Boateng, discloses that she is the Board President of Smell and Taste Association of North America (STANA), a patient advocacy group formed in 2020 to improve the quality-of-life for people with smell and taste disorders. She personally have no financial relationships with ineligible companies, however STANA received funding in exchange for promoting a Research Announcement for Cyrano Therapeutics, a startup company focused on developing a treatment for smell dysfunction. She will not mention anything related to it in any of her talks or conversations, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Jayant Pinto, MD, discloses he has relevant financial relationships with commercial interests in the following area: Advisory Board/Site Investigator for Sanofi/Regeneron Speaker’s Bureau, and Advisory Board for Optinose Speaker’s Bureau. These financial relationships are not relevant to the topic of this CME activity. His presentation will only contain data from his original work and peer reviewed publications, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Richard Doty, PhD, discloses that he is the president of Sensonics International, the owner and maker of University of Pennsylvania Smell Identification Test (UPSIT). His presentation will only contain data from his original work and peer reviewed publications, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

John Hays, PhD, discloses that he is a named co-inventor of patent application for the ArOMa-T smell test originally created with competitive funding from the National Institutes of Health. He is also co-founder of a startup company, Redolyn LLC, that may potentially license this technology from the University of Florida, Penn State, & Arizona. His presentation will only contain data from his original work and peer reviewed publications, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Linda Barlow, PhD, discloses she has relevant financial relationships with commercial interests in the following area: Advisory Board member of Nestle Health Science. This financial relationship is not relevant to the topic of this CME activity. Her presentation will only contain data from her original work and peer reviewed publications, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Pamela H. Dalton, PhD, discloses that she is a named co-inventor of patent application for the SCENTinel smell test, originally created with competitive funding from the National Institutes of Health. She participates in the distribution of potential revenue from licensing of the patent to Ahersla Health, LLC through the institutional patent policy. The license and the distribution of any revenue is managed by administrators at Monell and she have no input or control. Her presentation will only contain data from her original work and peer reviewed publications, and not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Jeb M. Justine, MD, discloses he has relevant financial relationships with commercial interests in the following area: consultant and speaker for Medtronic, to improve drills used in surgery. This financial relationship is not relevant to the topic of this CME activity. His presentation will not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Joshua Levy, MD MPH MS, discloses he has relevant financial relationships with commercial interests in the following areas: advisor to Sanofi/Regeneron and GSK, all ended; receiving research funding from Sanofi; and Board of director to journal International Forum of Allergy and Rhinology. His presentation will not include discussion of unapproved or “off-label” usage of commercial products and/or devices.

Educational Objectives
At the conclusion of this activity, learners will be able to:
• Learn about advancements in chemosensory diagnostics.
• Understanding existing novel smell and taste testing methods and how they can make us better medical providers.
• Identifying a roadmap to implement smell and taste testing routinely in the clinic.
• Harnessing the power of social media to communicate about the consensus reached on the need and advantages of smell and taste routine testing

Acknowledgement

We would like to thank the following exhibitors for their participation.

Berjé
Mary Bertino
Burghart North America
Aromha, Inc

Sensify, Inc.
Ahersla Health, Inc.
Sensonics International
Estenda Solutions, Inc.

Agenda Disclaimer

This activity is presented for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations of recognized expertise in their field.

No further reproduction or distribution is permitted by electronic transmission or any other means. The presentations at this conference are the intellectual property of the presenter and require his/her permission for further use.

RECCOMENDED (if applicable)

To access your continuing medical education certificate:

• Launch your internet browser and go to the CCME web address: http://ccme.osu.edu
• Enter the email address you used to create your OSU CCME account as your username.
• Type in your password, and click Log In.
  o If you do not remember your password, click the Forgot Your Password? link.
  o If you mailed in your registration, an account may have been created for you with your email address as your username and "changeme" as your password.
  o If you need additional assistance, you can contact the CCME office at 614-293-3576.
• Once logged in, click on the orange “My Account” button.
• On the next page, click the “Credits and Certificates” icon.
• You will be able to search for credits earned in a specified date range, by activity type or individual activities.
• To print individual event certificates, click on the “Print Certificate for this Event” icon (last icon to the right) that corresponds with the event title.

Please allow 2 to 4 weeks upon conclusion of the activity for CME credit to be applied to your CCME account. CME credits should be available to print at that time.

Need assistance or have questions? Call the OSU CCME office at (614) 293-3576.